tbuckley/cabot-search huggingface dataset:
Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses
Authors: David Druzd, Olga Matveeva, Louise Ince, Ute Harrison, Wenyan He, Christoph Schmal, Hanspeter Herzel, Anthony H. Tsang, Naoto Kawakami, Alexei Leliavski, Olaf Uhl, Ling Yao, Leif Erik Sander, Chien-Sin Chen, Kerstin Kraus, Alba de Juan, Sophia Martina Hergenhan, Marc Ehlers, Berthold Koletzko, Rainer Haas, Werner Solbach, Henrik Oster, Christoph Scheiermann
Journal: Immunity (2017)

Lymphocytes circulate through lymph nodes (LN) in search for antigen in what is believed to be a continuous process. Here, we show that lymphocyte migration through lymph nodes and lymph occurred in a non-continuous, circadian manner. Lymphocyte homing to lymph nodes peaked at night onset, with cells leaving the tissue during the day. This resulted in strong oscillations in lymphocyte cellularity in lymph nodes and efferent lymphatic fluid. Using lineage-specific genetic ablation of circadian clock function, we demonstrated this to be dependent on rhythmic expression of promigratory factors on lymphocytes. Dendritic cell numbers peaked in phase with lymphocytes, with diurnal oscillations being present in disease severity after immunization to induce experimental autoimmune encephalomyelitis (EAE). These rhythms were abolished by genetic disruption of T cell clocks, demonstrating a circadian regulation of lymphocyte migration through lymph nodes with time-of-day of immunization being critical for adaptive immune responses weeks later.
P1.05-024 Preoperative Neuron-Specific Enolase to Albumin Ratio is a Prognostic Biomarker for Patients with Operable Non-Small-Cell Lung Cancer
Authors: Hong Ren, Xiang Li, Boxiang Zhang, Yiwen Zhang, Litao Yang, Guodong Xiao, Xiao Gao, Guanghong Huang, Peili Wang, Huangzhen Wang, Chengcheng Yang, Sida Qin
Journal: Journal of Thoracic Oncology (2017)
Frontal fibrosing alopecia
Authors: L. Bomar, A. McMichael
Journal: British Journal of Dermatology (2017)

Frontal fibrosing alopecia (FFA) is a primary cicatricial alopecia first described by Kossard in 1994. It is considered a clinical variant of lichen planopilaris (LPP). In the last two decades, there have been an explosion of cases worldwide. While predominately seen in Caucasian, post-menopausal women, it has been reported in various ethnicities including African-Americans, Hispanics, Asians, and Indians as well as in pre-menopausal women and men.1-5 Characterized by progressive, scarring frontotemporal hair loss with perifollicular erythema, follicular keratinization, and reduced follicular orifices, the most common finding is bandlike recession of the scalp hairline.1-5 Accompanying features include eyebrow thinning, eyelash loss, body hair loss, facial papules, lonely hairs, and occipital alopecia.1-5 While typically asymptomatic, pruritus and trichodynia can occur. Eyebrow thinning often presents prior to scalp hairline regression and has been seen with milder hairline regression compared to individuals who do not experience eyebrow thinning first.2-4 Other dermatoses seen in patients with FFA include lichen planus on regions other than the scalp and lichen planus pigmentosus in non-Cacuasians.

This article is protected by copyright. All rights reserved.
Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori –related chronic gastritis: a prospective randomized study in China
Authors: L. Wang, Z. Lin, S. Chen, J. Li, C. Chen, Z. Huang, B. Ye, J. Ding, W. Li, L. Wu, Y. Jiang, L. Meng, Q. Du, J. Si
Journal: Clinical Microbiology and Infection (2017)

ObjectivesTo investigate the effectiveness of 10-day bismuth-containing quadruple (B-quadruple) treatment as first-line therapy in patients with Helicobacter pylori–related chronic gastritis.MethodsA randomized controlled trial was conducted from October 2011 to December 2013 in Zhejiang, China, including patients with H. pylori–related chronic gastritis who were randomly provided either 10-day omeprazole-based triple therapy (OM-triple; omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily) or 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily). H. pylori status, pathologic findings and dyspeptic symptoms were assessed at baseline and after 3 months. The primary outcome was H. pylori eradication rates by intention-to-treat (ITT) and per-protocol (PP) analyses. The secondary outcomes were the histologic and symptomatic benefits from H. pylori eradication.ResultsA total of 351 patients with H. pylori–related chronic gastritis were recruited. The eradication rates of the OM-triple and B-quadruple groups were 58.4% (108/185) and 86.1% (143/166) respectively according to ITT analysis (p <0.01). PP rates of H. pylori eradication were 63.2% (108/171) and 92.3% (143/155) respectively (p <0.01). According to the PP analysis, active and chronic inflammation in gastric mucosa was substantially improved in all treated patients (n=326). However, pathologic atrophic gastritis and intestinal metaplasia did not regress in both groups (n=326). The reduction of dyspeptic symptoms score was significantly higher in the B-quadruple group than in the OM-triple group (0.59±0.057 vs. 0.39±0.046) (p <0.01).ConclusionsTen-day B-quadruple therapy is more effective than OM-triple therapy as first-line therapy for patients with H. pylori–induced chronic gastritis in China.
Efficacy of Lenalidomide in Different Clinical Settings in Patients with Relapsed or Progressive Multiple Myeloma: Updated Analysis of 111 Cases of the Spanish Compassionate Use Program
Authors: A. Alegre, B. Aguado, P. Giraldo, P. Cánovas, A. Ibáñez, I. Castillo, M. Blanes, E. Ríos, J.N. Rodríguez, L. Palomera, MT Hernández, A. Oriol, E. Sancho, C. Menchaca, J. Vercher, AP González, M.J. Arilla, G. Ramírez, R. Pérez, A. Asensio, Javier De la Serna, S. Osorio, C. Aguilar, V. Ansó, J.M. Calvo, M. Casanova, M. Fuertes, J.L. Guzmán, L. López, A. López, J.L. Olalla, J.M Hernández, P. Ríos, L. Villalon, I. García, A. García, S. Larregla, F. Lara, J.L. Lahuerta
Journal: Blood (2008)
Is CD47 an innate immune checkpoint for tumor evasion?
Authors: Xiaojuan Liu, Hyunwoo Kwon, Zihai Li, Yang-xin Fu
Journal: Journal of Hematology & Oncology (2017)

Cluster of differentiation 47 (CD47) (also known as integrin-associated protein) is a ubiquitously expressed glycoprotein of the immunoglobulin superfamily that plays a critical role in self-recognition. Various solid and hematologic cancers exploit CD47 expression in order to evade immunological eradication, and its overexpression is clinically correlated with poor prognoses. One essential mechanism behind CD47-mediated immune evasion is that it can interact with signal regulatory protein-alpha (SIRPα) expressed on myeloid cells, causing phosphorylation of the SIRPα cytoplasmic immunoreceptor tyrosine-based inhibition motifs and recruitment of Src homology 2 domain-containing tyrosine phosphatases to ultimately result in delivering an anti-phagocytic—"don't eat me"—signal. Given its essential role as a negative checkpoint for innate immunity and subsequent adaptive immunity, CD47-SIRPα axis has been explored as a new target for cancer immunotherapy and its disruption has demonstrated great therapeutic promise. Indeed, CD47 blocking antibodies have been found to decrease primary tumor size and/or metastasis in various pre-clinical models. In this review, we highlight the various functions of CD47, discuss anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborate on the clinical potential of CD47 blockade. We argue that CD47 is a checkpoint molecule for both innate and adaptive immunity for tumor evasion and is thus a promising target for cancer immunotherapy.
P2.04-052 Promoter Hypermethylation of DNA Mismatch Repair Gene hMLH1 of Lung Cancer in Chromate-Exposed Workers
Authors: Mitsuhiro Tsuboi, Kazuya Kondo, Koichiro Kajiura, Hiromitsu Takizawa, Toru Sawada, Naoya Kawakita, Hiroaki Toba, Yukikiyo Kawakami, Mitsuteru Yoshida, Akira Tangoku
Journal: Journal of Thoracic Oncology (2017)
The association of geography with the primary treatment of prostate cancer in Wisconsin.
Authors: J. P. Cetnar, J. M. Hampton, A. A. Williamson, D. Wang, J. F. Wilson, J. B. Owen, L. A. Stephenson, A. Trentham-Dietz
Journal: Journal of Clinical Oncology (2011)

e16528 Background: We explored the relationship between geography and primary treatment of localized prostate cancer in Wisconsin in 2004. We hypothesized that patients in rural settings may be more likely to receive non-curative treatment. Methods: Certified, trained cancer registrars reviewed and abstracted the inpatient and outpatient records of 1,096 randomly-chosen localized prostate cancer cases to determine patient demographics, tumor characteristics, work-up, and treatment. Patients’ residential addresses were geocoded and linked to census tracts (2000 U.S Census) to determine urbanicity. The percent of census tracts classified as urban was categorized into three groups – urban (100% urban), mixed (1%-99% urban), and rural (0% urban). Rural-Urban Commuting Areas (RUCAs) were assigned to each case by census tract and categorized as either urban-focused, large rural/town-focused, small rural town focused, or isolated small rural town focused. Distance from residence to nearest radiation oncology facility was calculated. Curative treatment was defined as having surgery or radiation as the first course of treatment, while non-curative treatment was defined as having hormone therapy only or active surveillance. Logistic regression models -- adjusting for potential confounders -- estimated odds ratios (OR) and 95% confidence intervals (CI) of receiving non-curative treatment by geography. Results: 39.0% of cases lived in urban census tracts, while 41.3% lived in mixed and 19.7% lived in rural tracts. Hormone-only or active surveillance was received by 15.4% of the cases. Relative to urban cases, the OR for non-curative treatment was 1.01 (CI: 0.59-1.74) for mixed cases and 0.96 (CI: 0.52-1.77) for rural cases. For the analysis of the RUCA categorization, no association was found for non-curative treatment. No linear trend existed between non-curative treatment and distance to nearest radiation oncology facility (p-value = 0.92 for continuous distance). Conclusions: Neither residential urban/rural status nor distance to nearest radiation oncology facility was associated with non-curative treatment in this sample of Wisconsin residents diagnosed with prostate cancer in 2004.
Kinetics of CD34+ Cells in the Peripheral Blood of Patients with Primary Myelofibrosis Undergoing Splenectomy
Authors: Rita Campanelli, Margherita Massa, Elisa Bonetti, Gianluca Viarengo, Vittorio Rosti, Elisabetta Gattoni, Enza Moretti, Gaetano Bergamaschi, Laura Villani, Marco Lucioni, Laura Bandiera, Roberta Riboni, Gianni Barosi
Journal: Blood (2008)
P1.02-061 Kinase Fusions in Non-Small Cell Lung Carcinoma Identified by Hybrid Capture Based ctDNA Assay
Authors: Lauren Young, Siraj Ali, Alexa Schrock, Mark Kennedy, Laurie Gay, Justin Allen, James Suh, Victoria Wang, Eric Bernicker, Sai-Hong Ignatius Ou, Davood Vafai, Jeffrey Ross, Phil Stevens, Vincent Miller
Journal: Journal of Thoracic Oncology (2017)
Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease
Authors: David A. Jacobsohn, Mukta Arora, John P. Klein, Joseph H. Antin, Brian J. Bolwell, Michael Boyiadzis, Jean-Yves Cahn, Mitchell S. Cairo, Corey S. Cutler, Mary E.D. Flowers, Robert P. Gale, Anna Hassebroek, Roger H. Herzig, Mary M. Horowitz, Luis Isola, Thomas R. Klumpp, Stephanie J. Lee, Effie W. Petersdorf, Stella Santarone, Harry C. Schouten, Stephen Spellman, Alvaro Urbano, Daniel J. Weisdorf, John R. Wingard, Steven Z. Pavletic
Journal: Blood (2010)
P160 Use of omalizumab in fungal allergic asthma
Authors: HV Patel, B Kane, P Foden, LJ Holmes, GOG Tavernier, TB Morris, DM Ryan, RM Niven
Journal: Thorax (2016)

<h3>Background</h3> The monoclonal anti-IgE agent Omalizumab holds an established place in the management of severe allergic asthma patients (GINA Step 5). Fungal allergic asthma possesses added complexity as fungi are ubiquitous in our environment and are capable of not only triggering asthma, but may grow, colonise and infect host tissue. Current treatment approaches include: Allergen avoidance, mucus reduction, control of bacterial infection, control of inflammation, reducing fungal burden and recently blockade of allergy using Omalizumab. <h3>Aims/purpose</h3> Investigate the response to Omalizumab in severe asthma patients who are sensitised to fungal allergens compared to those who are non-fungal allergic. Current literature describes the use of Omalizumab in fungal allergic airways disease, though published data takes the form of case reports/series with limited total population. <h3>Methods</h3> Retrospective cohort study of severe asthma patients treated with Omalizumab (n = 168). Patients were grouped into fungal or non-fungal allergy status, followed by a comparison of the change in a variety of clinical and physiological outcomes at 16 weeks and 52 weeks from baseline between these two groups. The change in Asthma Quality of Life Questionnaire (AQLQ) between baseline and 16 weeks was utilised as the primary outcome. Groups will be compared using an unpaired t-test or Chi-squared test, as appropriate, to test for non-inferiority (threshold −0.25) in the fungal allergic group compared to the non-fungal allergic group. <h3>Results</h3> The fungal allergic group (n = 76) was found to have a mean AQLQ difference between baseline and 16 weeks of +1.34 ( ± 1.25). When compared to the non-fungal allergic cohort, the fungal allergic group was found to have a statistically significant mean AQLQ difference between baseline and 16 weeks of −0.41 (95% CI: −0.14 – −0.81). See Figure 1. <h3>Conclusion</h3> Fungal allergic patients have a less profound AQLQ response to Omalizumab than non-fungal allergic although the benefit is still clinically significant in the majority of cases. The reduced benefit is statistically different in terms of change, though it does not fulfil the a-priori threshold for non-inferiority.
PUB024 Real-Time Computed Tomography Fluoroscopy Guidance in a Rabbit Model of Solitary Lung Cancer
Authors: Hyun Koo Kim, Byeong Hyeon Choi, Hwan Seok Young, Yu Hua Quan, Jiyun Rho, Jae Seon Eo, Kook Nam Han, Young Ho Choi
Journal: Journal of Thoracic Oncology (2017)
An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment
Authors: Anil N. Makam, Oanh K. Nguyen
Journal: Circulation (2017)

Overtreatment is pervasive in medicine and leads to potential patient harms and excessive costs in health care. Although evidence-based medicine is often derided as practice by rote algorithmic medicine, the appropriate application of key evidence-based medicine principles in clinical decision making is fundamental to preventing overtreatment and promoting high-value, individualized patient-centered care. Specifically, this article discusses the importance of (1) using absolute rather than relative estimates of benefits to inform treatment decisions; (2) considering the time horizon to benefit of treatments; (3) balancing potential harms and benefits; and (4) using shared decision making by physicians to incorporate the patient’s values and preferences into treatment decisions. Here, we illustrate the application of these principles to considering the decision of whether or not to recommend intensive glycemic control to patients to minimize microvascular and cardiovascular complications in type 2 diabetes mellitus. Through this lens, this example will illustrate how an evidence-based medicine approach can be used to individualize glycemic goals and prevent overtreatment, and can serve as a template for applying evidence-based medicine to inform treatment decisions for other conditions to optimize health and individualize patient care.
P2.06-005 Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC
Authors: David Planchard, Mark Kris, Benjamin Besse, Rebecca Hozak, Shuang He, Frank Gan, Katharina Wolff, Bo Chao, Helena Yu
Journal: Journal of Thoracic Oncology (2017)
The effect of metformin (M) on overall survival (OS) of patients (Pts) with colorectal cancer (CRC) treated with chemotherapy (CTX).
Authors: M. Bansal, E. Siegel, R. Govindarajan
Journal: Journal of Clinical Oncology (2011)

2608 Background: Prior observations had shown the beneficial effects of M on survival of Pts with CRC. This study was conducted to evaluate the effect of M on Pts treated with CTX. Methods: A retrospective study of 5052 Pts with CRC from 10/01/1996 to 3/31/2010 was conducted from the VA cancer registry data base (VISN16). CRC Pts who received CTX were analyzed for the effect of M on OS using stratified Cox regression with M exposure as a time-dependent covariate. Stratification factors were treatment (TX) modalities (CTX details, S and RT). Results: 1,078 of the 5,052 Pts with CRC received CTX. 571 (33.4%) had DM,141 were on M. There were 37(2.2%) females, 1,207 (70.1%) Caucasians, 408 (23.9%) African Americans, 93 (6.0%) other/unknown. Median age (quartiles) at CRC diagnosis was 64 (57–71) years (Yrs). CTX details: 796 (46.6%) single agent, 833 (48.8%) multi-agent, 79 (4.6%) not specified (NOS). 1362 (79.7%) had S, 639 (37.4%) had RT. 24 deaths occurred during 339 yrs of post-M follow-up (0.07 deaths/year/person[d/y/p]) , 879 deaths during 6930 Yrs. of M-free follow-up (0.13 d/y/p). Without stratification, the hazard ratio (HR) (95% CI; p value) was 0.61 (0.41–0.91; p=0.017) for CTX+M compared to CTX alone. Adjusted HR post stratification on S, RT, and CTX details was 0.59 (0.39–0.89; p=0.012) for CTX+M compared to CTX alone. Conclusions: Metformin appears to improve the OS rate of Pts with CRC treated with CTX. There was no influence of the TX modalities (S, CTX, and RT) on the effect of M. M exposure summary and stratified Cox-regression results of Pts with CRC treated with CTX. DM TX Exposure summary Adjusted HR3 (95% CI) P value N (%1) Yrs (%2) Deaths No Metformin 1,567 (91.7%) 6,929.8 (95.3%) 879 1.00 (reference) ----- +Metformin 141 (8.3%) 339.2 (4.7%) 24 0.59 (0.39–0.89) 0.0122 1% of total no of 1,708 Pts. 2% of total follow-up of 7269.1 yrs. 3HR from stratified Cox regression of OS on ±M, with M as time-dependent covariate. Stratification factors were: S (yes/no), RT (yes/no) and CTX (single-agent/multi-agent/NOS).
JCES01.15 Analysis of Genomic Alterations and Heterogeneity in Pulmonary Adenoid Cystic Carcinoma by Next-Generation Sequencing
Authors: Min Li, Bingrong Zhao, Pengbo Deng, Liming Cao, Huaping Yang, Qihua Gu, Chengping Hu
Journal: Journal of Thoracic Oncology (2017)
Association of Janus Kinase 2(JAK2) A830G Polymorphism with Acute Leukemia Susceptibility.
Authors: Bao-An Chen, Yue-Jiao Zhong, Ji-feng Feng, Yu-feng Li, Jia-Hua Ding, Chong Gao, Jian Cheng, Guo-Hua Xia, Ning Sun, Ning-Na Chen, Xiao-ping Zhang, Pei-pei Xu, Xiao-Ping Pei, Jun Qian, Lu Cheng, Zu-hong Lu
Journal: Blood (2009)
Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)
Authors: Mahran Shoukier, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Zeev Estrov, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Steven M. Kornblau, Elizabeth M Burton, Susan O'Brien, Jorge E Cortes
Journal: Blood (2011)
P2.01-029 Tumor B7-H3 (CD276) Protein Expression, Smoking History, and Survival in Lung Adenocarcinoma Patients
Authors: Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Rie Sakakibara, Hironori Ninomiya, Sophia Subat, Hiroko Nagano, Kimie Nomura, Sakae Okumura, Tomoko Shibutani, Yuichi Ishikawa
Journal: Journal of Thoracic Oncology (2017)
OA24.05 The Nordic HILUS-Trial - First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors
Authors: Karin Lindberg, Per Bergström, Odd Terje Brustugun, Silke Engelholm, Vitali Grozman, Morten Hoyer, Kristin Karlsson, Azza Khalil, Charlotte Kristiansen, Ingmar Lax, Britta Löden, Jan Nyman, Gitte Persson, Lotte Rogg, Peter Wersäll, Rolf Lewensohn
Journal: Journal of Thoracic Oncology (2017)
The CXCR4 Antagonist AMD3100 Impairs Survival of AML Cells and Induces Their Differentiation.
Authors: Sigal Tavor, Manny Eisenbach, Jasmine Jacob-Hirsch, Tammar Golan, Isabelle Petit, Katz Ben-Zion, Sigi Kay, Shoshana Baron, Ninette Amariglio, Varda Deutsch, Elizabeth Naparstek, Gideon Rechavi
Journal: Blood (2008)
P3.02c-034 A Single Institution Experience with Immunotherapy as an Effective Therapy Approach of Advance Non-Small Cell Lung Cancer (NSCLC)
Authors: Julia Martínez Pérez, Inmaculada Sanchez, Alejandro Falcon Gonzalez, Miriam Alonso, Maria Jose Flor Oncala, Jesus Corral
Journal: Journal of Thoracic Oncology (2017)
MA03.06 Cost Effectiveness of Chest Scan Screeing for Lung Cancer in Abestos Occupational Exposure Subjects: A Model Based Study
Authors: Juliette Vella-Boucaud, Jean Claude Pairon, Anne Duburcq, Patrick Brochard, Soizic Chamming'S, Amandine Luc, Bruno Detournay, Christophe Paris, Pascal Andujar, Christos Chouaid
Journal: Journal of Thoracic Oncology (2017)
Is poliomyelitis a serious problem in developing countries? - the Danfa experience.
Authors: D. D. Nicholas, J. H. Kratzer, S. Ofosu-amaah, D. W. Belcher
Journal: BMJ (1977)

Children were examined for lameness in the Danfa Project district of rural Ghana to assess the impact of endemic poliomyelitis and to test a widely held hypo thesis that paralytic poliomyelitis is relatively rare in such districts (less than 1 per 1000 children affected). The observed prevalence of lameness attributable to polio myelitis was 7 per 1000 school-aged children, and the annual incidence is estimated to be at least 28 per 100 000 population. Although no evidence for an epidemic was found, these rates are comparable with those in the USA and Europe during the years of severe epidemics and indicate that a high price is being paid in the Danfa district for the natural acquisition of immunity. As a result, immunisation against poliomyelitis has been given high priority. A teacher questionnaire was also
Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice
Authors: Takashi Honda, Masatoshi Ishigami, Fangqiong Luo, Ma Lingyun, Yoji Ishizu, Teiji Kuzuya, Kazuhiko Hayashi, Isao Nakano, Tetsuya Ishikawa, Guo-Gang Feng, Yoshiaki Katano, Tomoya Kohama, Yasuyuki Kitaura, Yoshiharu Shimomura, Hidemi Goto, Yoshiki Hirooka
Journal: Metabolism (2017)
P3.02b-008 Quantification and Monitoring of Treatment Response in EGFR Mutant NSCLC Patients by Digital-PCR in Plasma cftDNA
Authors: Vienna Ludovini, Annamaria Siggillino, Maria Sole Reda, Fortunato Bianconi, Rita Chiari, Sara Baglivo, Lorenza Pistola, Francesca Romana Tofanetti, Roberta Matocci, Clelia Mencaroni, Giulio Metro, Chiara Bennati, Vincenzo Minotti, Lucio Crinò
Journal: Journal of Thoracic Oncology (2017)
P2.05-044 Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases
Authors: Juliane Hoerner-Rieber, Nasrin Abbassi-Senger, Sonja Adebahr, Nicolaus Andratschke, Oliver Blanck, Marciana Duma, Michael J. Eble, Iris Ernst, Michael Flentje, Sabine Gerum, Peter Hass, Christoph Henkenberens, Guido Hildebrandt, Detlef Imhoff, Henning Kahl, Robert Krempien, Nathalie Desirée Klass, Fabian Lohaus, Frank Lohr, Cordula Petersen, Elsge Schrade, Jan Streblow, Lorenz Uhlmann, Andrea Wittig, Florian Sterzing, Matthias Guckenberger
Journal: Journal of Thoracic Oncology (2017)
Salvage Therapy with Intravenous Bortezomib, Melphalan and Dexamathasone in Previously Treated Myeloma Patients.
Authors: Francesco Di Raimondo, Annalisa Chiarenza, Alessandra Romano, Vittorio Del Fabro, Luciana Schinocca, Paolo Fiumara, Concetta Conticello, Gabriella Amato, Giuseppe A. Palumbo, Rosario Giustolisi
Journal: Blood (2007)